Amgen Stock Hovers Near Record Highs Amid Double-Digit Revenue Growth

Amgen's stock price remains near record highs in August 2026, supported by double-digit revenue growth in Q2 2026 and a confirmed cash dividend of $2.52 per share for shareholders.

The biotechnology company reported total revenue of $10.1 billion in the second quarter, representing a 10 percent increase from the same period in 2025. Product sales growth was driven primarily by higher volumes across key therapies, with product sales reaching $9,537 million compared to $8,771 million in Q2 2025.

Amgen's full-year financial guidance has been updated based on the second-quarter performance, with non-GAAP earnings per share expected to be between $22.30 and $23.50, and a tax rate between 15.0 percent and 16.5 percent.